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Abstract: Despite the successes of antiretroviral therapy (ART), HIV-associated neurocognitive 
disorders remain prevalent in infected people. This is due, in part, to incomplete ART penetration 
across the blood–brain barrier (BBB) and lymph nodes and to the establishment of viral sanc-
tuaries within the central nervous system. In efforts to improve ART delivery, our laboratories 
developed a macrophage-carriage system for nanoformulated crystalline ART (nanoART) 
(atazanavir, ritonavir, indinavir, and efavirenz). We demonstrate that nanoART transfer from 
mononuclear phagocytes (MP) to human brain microvascular endothelial cells (HBMEC) can 
be realized through cell-to-cell contacts, which can facilitate drug passage across the BBB. 
Coculturing of donor MP containing nanoART with recipient HBMEC facilitates intercellular 
particle transfer. NanoART uptake was observed in up to 52% of HBMEC with limited cyto-
toxicity. Folate coating of nanoART increased MP to HBMEC particle transfer by up to 77%. 
To translate the cell assays into relevant animal models of disease, ritonavir and atazanavir 
nanoformulations were injected into HIV-1-infected NOD/scid-γ
c
null mice reconstituted with 
human peripheral blood lymphocytes. Atazanavir and ritonavir levels in brains of mice treated 
with folate-coated nanoART were three- to four-fold higher than in mice treated with noncoated 
particles. This was associated with decreased viral load in the spleen and brain, and diminished 
brain CD11b-associated glial activation. We postulate that monocyte-macrophage transfer of 
nanoART to brain endothelial cells could facilitate drug entry into the brain.
Keywords: nanoART, folate, monocyte-endothelial cell interactions, blood–brain barrier, 
antiretroviral therapy, nanomedicine
Introduction
HIV enters the central nervous system (CNS) in the early stages of infection.  Following 
sustained viral replication in brain mononuclear phagocytes (MP) (blood-borne 
macrophages and microglia) and progressive immune suppression, HIV incites glial 
inflammation and injures neurons (for recent reviews, see1,2). Such pathobiologic 
events result in behavioral, motor, and cognitive impairments that range from clini-
cally asymptomatic to frank dementia, referred to as HIV-associated neurocognitive 
disorders (HAND).3,4
Despite the effectiveness of combination antiretroviral therapy (cART) in reducing 
morbidity and mortalities, HAND remain a highly prevalent comorbid condition.5 This 
may be due, in part, to the poor ART penetration into the CNS and continuance of the 
brain viral reservoir.6–9 Alternatively, HAND may be affected by neurotoxicities seen 
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as a consequence of long-term therapies that penetrate the 
nervous system.10 Notably, ART drugs are often substrates for 
efflux transporters such as P-glycoproteins and multidrug-
resistant associated proteins present on brain endothelial 
cells.7,11,12 Thus, even when ART can reduce viral load in the 
periphery, productive HIV infection can continue in the CNS. 
Increasing ART penetration into the brain could help reduce 
the CNS viral load and diminish injury and death of neural 
cells. Most importantly, site-directed therapies, as developed 
through nanoformulated crystalline ART (nanoART), could 
reduce inherent ART toxicities.
A means to reduce the viral reservoir in the CNS while 
limiting toxicities is to increase brain- or region-specific 
ART access. This may occur by repackaging traditional 
antiretroviral medications into nanoART vectors to facili-
tate cell-based delivery of drug and, as such, improve ART 
pharmacokinetics and biodistribution.13 To this end, our 
prior works demonstrated limited cytotoxicity of nanoART 
to monocytes and macrophages14 and efficient macrophage 
uptake, distribution, and release of nanoART in both in vitro 
and animal models of human disease.15–17 Macrophage drug 
carriers were able to deliver ART to the same tissue sites 
where active HIV-1 replication ensues.15–21 However, what 
remained unanswered was the effect of nanoART on specific 
drug delivery into the CNS. To this end, we investigated the 
effects of 15 nanoformulations of atazanavir (ATV), ritonavir 
(RTV), indinavir (IDV), and efavirenz (EFV) manufactured 
using different surfactants, including nanoART containing 
folate-coated surfactant (Table 1), on primary human brain 
microvascular endothelial cells (HBMEC), and the effects 
of MP-endothelial cell interactions on nanoART uptake, 
distribution, and entry into the CNS. We demonstrate uptake 
of nanoART by HBMEC, and this was associated with limited 
endothelial cytotoxicity. We further demonstrate transfer 
of nanoART from MP to HBMEC during MP-endothelial 
contact, with higher transfer for folate-coated nanoART. 
Administration of folate-coated nanoART to an animal 
model of HIV/AIDS showed efficient antiretroviral activity, 
drug-brain penetration, and decreased CNS inflammation in 
HIV-1-infected and nanoART-treated animals. We postulate 
that folate modification and endothelial uptake of nanoART 
could facilitate drug entry into the brain.
Materials and methods
Preparation and characterization  
of nanoART
Freebase forms of RTV and EFV were obtained from Shengda 
Pharmaceutical Co (Zhejiang, People’s Republic of China) 
and Hetero Labs, Ltd (Hyderabad, India). The sulfate forms 
of IDV and ATV were purchased from Longshem Co (Shang-
hai, People’s Republic of China) and Gyma Laboratories of 
America Inc (Westbury, NY). The free bases of IDV and ATV 
were made using a 1N NaOH solution. Using the surfactants 
listed in Table 1, nanoART were manufactured from these 
protease inhibitors (IDV, RTV, ATV) and non-nucleoside 
reverse transcriptase inhibitor (EFV) as we previously 
Table 1 Physical characteristics of drug nanoparticles
Drug Formulation Method Surfactant Size (nm) Zeta potential (mV)
IDV H1008 Homogenized P188, Tween 80 1600 -29.5
H1013a Homogenized P188, mPEG2000-DSPE 861 -21.8
H1013b Homogenized P188, mPEG2000-DSPE 819 -23.6
M1004 Milled P188, SDS 252 -40.58
RTV H2014 Homogenized mPEG2000-DSPE 500 -26.2
H2009 Homogenized mPEG2000-DSPE 204 -21.1
H2013 Homogenized P188, mPEG2000-DSPE 613 -26.7
H2019 Homogenized P407 471 -21.5
H2020 Homogenized 40% folate-P407/60% P407 454 -18.3
M2001 Milled P188 347 -13.5
M2006 Milled P188, mPEG2000-DSPE 443 -25.93
ATV M3001 Milled P188 281 -15.3
H3019 Homogenized P407 383 -10.2
H3020 Homogenized 40% folate-P407/60% P407 365 -24.6
EFV P4004 Sonication PLGA, PVA, CTAB 300 +7.4
Fluconazole H5013 Homogenized P188, mPEG2000-DSPE 1143 -25.3
H5014 Homogenized mPEG2000-DSPE 914 -27.4
M5004 Milled P188, SDS 530 -20.47
M5006 Milled P188, mPEG2000-DSPE 894 -26.52
Abbreviations: ATV, atazanavir; CTAB, cetyltrimethyl ammonium bromide; EFV, efavirenz; IDV, indinavir; mPEG2000-DSPE, N-(carbonyl-methoxypolyethyleneglycol 2000)-
1,2 sn-glycero-3-phosphoethanolamine; PLGA, poly(lactic-coglycolic acid); PVA, polyvinyl alcohol; RTV, ritonavir; SDS, sodium dodecyl sulfate.
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described14,17,22 and as detailed in the data supplement. 
Drug concentration in the final  nanoART suspension was 
determined using high-performance  liquid chromatography 
(HPLC) as previously described.17  NanoART formulations 
were imaged by scanning electron microscopy as previously 
described.14,17,22
Synthesis of folate poloxamer 407  
(folate-P407)
Folate-P407 was synthesized for the preparation of targeted 
folate nanoART. Briefly, poloxamer 407 (P407, Sigma-
Aldrich, Saint Louis, MO) was activated with an eight-fold 
molar ratio of p-toluenesulfonyl chloride in dichloromethane 
(Sigma-Aldrich) with quantitative yield. The purified tosylated 
product was converted to azido-P407 by incubation with a six-
fold molar ratio of sodium azide in N,N-dimethylformamide 
(Sigma-Aldrich) at 100°C overnight. Azido-P407 was then 
reduced to amine-P407 using a four-fold molar ratio of 
triphenylphosphine in tetrahydrofuran. To conjugate folate 
onto P407, folic acid (Sigma-Aldrich) was first activated with 
N,N′-dicyclohexylcarbodiimide and N-hydroxysuccinimide 
in dimethyl sulfoxide (all from Sigma-Aldrich), then a four-
fold molar ratio of the resulting folate-N-hydroxysuccinimide 
ester was reacted with amine-P407 in dimethyl sulfoxide. 
The crude product was purified by precipitation in methanol 
and further purified with a Sephadex LH-20 column (GE 
Healthcare, Piscataway, NJ). A mixture consisting of 40% 
folate-P407 and 60% P407 was used to manufacture targeted 
folate nanoART through high-pressured homogenization.
Labeling of nanoART
NanoART were fluorescently labeled using lissamine rhodamine B 
1,2-dihexadecanoyl-sn-glycero-3- phosphoethanolamine, 
triethylammonium salt (excitation 560 nm, emission 580 nm), 
or the Vybrant 3,3′-dioctadecyloxacarbo-cyanine perchlorate 
(DiD) cell-labeling solution (excitation 644 nm: emission 
665 nm) (Invitrogen, Carlsbad, CA). For labeling, 1 mL nano-
ART suspension was mixed overnight with 5 µL of dye and 
nanoART pelleted by centrifugation at 20,000 × g for 5 minutes. 
NanoART particles were then washed at least five times with 
phosphate buffered saline (PBS) to remove all excess dye, and 
final drug concentration of the formulations was determined 
by HPLC.
Human monocyte isolation  
and cultivation
Monocytes were obtained from HIV-1, HIV-2, and hepatitis B 
seronegative donor leukopaks, separated by countercurrent 
centrifugal elutriation, and characterized as previously 
described.23,24 To obtain monocyte-derived macrophages 
(MDM), freshly elutriated monocytes were cultured for 
7 days in Dulbecco’s Modified Eagle Medium containing 
2 mM L-glutamine (Invitrogen), 10% heat-inactivated human 
serum, 100 µg/mL gentamicin, and 10 µg/mL ciprofloxacin 
(Sigma-Aldrich) in the presence of 1000 U/mL human recom-
binant macrophage colony-stimulating factor.
Brain endothelial cell culture  
and cytotoxicity assays
Primary HBMEC were isolated from brain tissue obtained 
during surgical removal of epileptogenic cerebral cortex 
in adult patients as described previously24,25 and provided 
by Dr Marlys Witte and Dr Michael Bernas (University of 
Arizona, Tuscon, AZ). These brain tissues were collected under 
institutional review board-approved protocol at the University 
of Arizona. Routine evaluation for von Willebrand factor, Ulex 
europeus lectin, and CD31 (all from Abcam,  Cambridge, MA) 
demonstrated that cells were .99% pure. Freshly isolated 
cells were cultured as we previously described,24,25 and cells 
at passage 2–4 were used in this study. To determine any 
potential toxic effects of nanoART on HBMEC, confluent 
cells were treated with nanoART at 0.1 mM to 0.27 mM 
for 2 hours at 37°C, 5% CO
2
. Following loading of each 
nanoformulation, cells were washed with serum-free culture 
media to remove excess drugs and cytotoxicity assessed over 
48 hours using alamarBlue™ assay (Invitrogen) according to 
the manufacturer’s instructions.
Endothelial-MP nanoART transfers
Primary HBMEC were cultured to confluence on glass 
coverslips as previously described.26 For endothelial-MDM 
communication, human MDM were loaded with 0.1 mM rho-
damine- or DiD-labeled nanoformulations of IDV, RTV, ATV, 
or EFV for 12 hours. Following nanoART loading, MDM 
were washed three times with PBS to remove any free nano-
ART, and cultured for 24 hours in drug-free media. Following 
the 24-hour culture, MDM media were collected and HBMEC 
were treated with this MDM-conditioned media for 2 hours. 
For endothelial-monocyte communication, freshly elutriated 
human monocytes were loaded with 0.1 mM rhodamine- or 
DiD-labeled nanoformulations of IDV, RTV, ATV, or EFV 
for 12 hours. Following nanoART loading, monocytes were 
washed three times with PBS to remove any free nanoART. 
Monocytes were then cocultured with endothelial cells for 
2 hours and HBMEC monolayers washed three to five times 
with PBS to remove monocytes.
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Immunofluorescence and confocal 
microscopy
Following endothelial-MDM and endothelial-monocyte 
coculture experiments, endothelial cells were washed, fixed, 
permeabilized with 0.1% triton X-100, and blocked for non-
specific binding with 3% bovine serum albumin in PBS. Cells 
were incubated with antibodies to the endothelial cell marker 
von Willebrand factor (Abcam), 1:50 dilution, for 1 hour at 
room temperature, followed by staining (1 hour in the dark 
at room temperature) with secondary antibodies coupled 
with Alexa-488 (Invitrogen) at 1:500 dilutions. For immu-
nofluorescence microscopy, stained cell monolayers were 
mounted in Prolong Gold antifade reagent containing DAPI 
(for nuclear staining) (Molecular Probes, Grand Island, NY) 
and examined using a fluorescent microscope (E800 Nikon, 
Melville, NY) connected to a color MagnaFire digital camera 
(Optronics, Goleta, CA). In separate experiments, HBMEC 
cultures were fluorescently labeled using the Vybrant 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine 
perchlorate (DiO) cell-labeling solution (excitation 484 nm: 
emission 501 nm) and cocultured for 2 hours with monocytes 
loaded with rhodamine- or DiD-labeled nanoART. HBMEC 
monolayers were then washed three to five times with PBS 
to remove monocytes, mounted in Prolong Gold, and ana-
lyzed by fluorescence or confocal microscopy. Microscopic 
images were processed with 20 iterations of two-dimensional 
deconvolution at low noise level using Autoquant X software 
package (Media Cybernetics, Bethesda, MD).
To determine the localization of nanoART in endothelial 
cells, the triple-labeled cell samples were examined under 
an Olympus FV500-IX 81 confocal laser scanning imag-
ing system. Several Z-series (0.5 µM optical sections) of 
images covering the apical and basal surfaces of the cells 
were collected from different areas of the cell samples using 
a sequential collection mode with triple laser lines excita-
tion (405 nm for nucleus stains; 488 nm for von Willebrand 
factor/ endothelial cell marker, and 543 nm for nanoART). For 
endothelial cells labeled with DiO and cocultured with mono-
cytes loaded with rhodamine- or DiD-labeled nanoART, the 
triple laser lines excitations were 405 nm for nucleus stains, 
484 nm for DiO/endothelial cells, and 543 nm or 644 nm for 
nanoART. Using the Olympus Fluoview imaging  acquisition/
analysis software, data processing/analysis and side view 
image projections were carried out from line scans at the 
XZ axis and YZ axis from the extended-focusing images 
(merged from z-optical images). For better demonstration of 
the cellular localization of the nanoART particles, the XZ or 
YZ lines were selected to a position over specific nanoART 
and nonspecific/background staining for comparison of their 
position in the same side view images.
Fluorescence-activated cell sorting
For fluorescence-activated cell sorting (FACS) quantifica-
tion of nanoART uptake by MP, monocytes or MDM were 
exposed to rhodamine- or DiD-labeled nanoART for 12 hours 
and washed three to five times with PBS to remove free 
nanoART. MP were then fixed by incubation in 1% para-
formaldehyde for 20 minutes, washed, resuspended in PBS, 
and analyzed by FACS using a FACScan flow  cytometer 
(BD Bioscience, San Jose, CA). The mean fluorescence 
channel and mean number of rhodamine-positive cells 
were derived using CellQuest software (BD Bioscience). 
To determine the levels of nanoART in MP and HBMEC 
following MP-endothelial communication, monocytes loaded 
with rhodamine- or DiD-labeled nanoART were cocultured 
for 2–4 hours with HBMEC (unlabeled or DiD-labeled), 
then washed three to five times to separate monocytes from 
endothelial cells. HBMEC and monocytes recovered from 
cocultures were then fixed by incubation in 1% paraform-
aldehyde for 20 minutes, washed, resuspended in PBS, and 
analyzed by FACS. The mean fluorescence channels and 
mean number of rhodamine-positive cells (monocytes), DiD-
positive cells (HBMEC), and HBMEC double positive for 
rhodamine and DiD were derived using CellQuest software 
(BD Bioscience). For all FACS analyses, each experimental 
condition was performed in triplicate.
Animals
Male NOD/scid-γ
c
null (NSG) mice were obtained from the 
University of Nebraska Medical Center breeding colony, 
established in 2005. This colony is housed in pathogen-free 
conditions in accordance with ethical guidelines for the care 
of laboratory animals at the National Institutes of Health, and 
all procedures were approved by the Institutional Animal 
Care and Use Committee.
Human cell isolation, transplantation,  
and viral infection
Human peripheral blood lymphocytes (PBL) were puri-
fied from leukopaks by countercurrent centrifugal elu-
triation23 and used to reconstitute the NSG mice. PBL were 
injected intraperitoneally into 8-week-old NSG mice at 
30 × 106 PBL/mouse. For viral infections, the macrophage-
tropic HIV-1
ADA
, was propagated in human MDM; viral 
cultures were screened and found to be negative for endo-
toxin (,10 pg/mL) by Limulus amebocyte lysate assays 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2376
Kanmogne et al
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
9.
93
.1
0.
13
2 
on
 0
3-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2012:7
(Associates of Cape Cod, Woods Hole, MA) and Mycoplasma 
ribosomal RNA (Gen-ProbeII, Gene Probe, San Diego, CA). 
The viral titer was assayed on MDM and determined to be 
105 tissue culture infectious dose
50
 (TCID
50
)/mL.
Biodistribution and antiretroviral  
activity of folate-coated nanoART
To determine the antiretroviral activity of folate-coated nano-
ART, NSG mice were reconstituted with PBL and infected 
7 days later with HIV-1
ADA
 (intraperitoneally) at a dose of 
104 TCID
50
/mouse. Two subcutaneous doses of folate-coated 
nanoART were administered, at 12 hours (Day 0) and 7 days 
after infection. NanoART were administered as folate-
P407-coated ATV and RTV (H3020 and H2020, Table 1), 
at 250 mg/kg each drug. This corresponded to a dose of 
20.3 mg/kg in humans based on an interspecies scaling factor 
of 12.3.27 Blood and tissues were collected on Day 14 after 
the initial (Day 0) drug administration for quantitation of drug 
levels, tissue viral load, and human cell reconstitution. Drug 
concentrations were determined by ultraperformance liquid 
chromatography tandem mass spectrometry as described 
previously.28
Quantitative real-time polymerase  
chain reaction
Total RNA was extracted from spleen sections and a half-
hemisphere of each brain using TRIzol (Invitrogen). RNA 
was reverse transcribed to cDNA using the Verso cDNA kit 
(Fisher, Pittsburgh, PA). Quantitative real-time polymerase 
chain reaction (qRT-PCR) was performed to determine the 
expression of HIV-1 gag, human CD45, and mouse CD11b 
and the endogenous control glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Taqman gene expression assays 
from Applied Biosystems (Carlsbad, CA) were used and the 
primer IDs were as follows: CD45: Hs00365634_g1, CD11b: 
Mm00434455_m1; and GAPDH: Hs99999905_m1. The 
primers and probe used for HIV-1 gag determination were 
as follows: forward, 5′-ACATCA AGC CAT GCA AAT -3′; 
reverse, 5′- ATC TGG CCT GGT GCAATAGG-3′; and 
probe (FAM), 5′-CATCAATGAGGAAGCTG CAGAATG 
GGA TAG A -3′ (TAMRA). Gene expression was calculated 
using the delta-delta CT method (Applied Biosystems).
Statistical analysis
The Student’s t-test was used for two-group analysis; multiple 
group comparisons were made by one- or two-way analysis 
of variance, and the general linear model procedures used 
GraphPad Prism 5.0d. Descriptive statistics for drug levels 
in vivo were summarized using median values due to the small 
sample size and non-normality of the data. Outcomes were 
compared between two groups using a Mann-Whitney test. 
The Tukey’s post-test procedure was employed for multiple 
comparisons. The threshold for significance was P <0.05.
Results
Manufacture and characterization  
of nanoART
The characteristics of the nanoART used in this study were 
previously described.14,17,22 Briefly, nanoART, prepared from 
freebase drugs, were manufactured as nanosized drug crystals 
coated with phospholipid surfactants (IDV, ATV, and RTV) or 
as drug dissolved in a poly(lactic-coglycolic acid) copolymer 
solution (EFV).14,17,22 The nanoART morphology and shape 
have been described in our previous publications.14,17,22 The 
physical properties of the nanosuspensions were similar in 
charge but varied in size (Table 1). The largest particle size was 
1600 nm (H1008) while the smallest was 204 nm (H2009). 
The charges of all particles were #-10 mV with the exclusion 
of P4004, which was +7.4 mV.14
Cytotoxicity of nanoART in HBMEC
NanoART showed limited cytotoxicity in human mono-
cytes and macrophages.14 Herein, we evaluate the toxicity 
of 15 independent ART nanoformulations manufactured by 
homogenization, wet milling, and sonication, in HBMEC. 
These included ten homogenized (three IDV, five RTV, and two 
ATV), four milled (IDV, RTV, and ATV), and one sonicated 
(EFV) nanoART (Table 1). Similar concentrations of free 
ART drugs and similar amounts of each surfactant without 
drug were used as controls. Viability and functional tests were 
performed on HBMEC for each nanoART at 0.1 mM based 
on prior studies,14–17 with the exception of H2009, which was 
investigated at 0.18 mM and 0.27 mM, based on prior toxicity 
profiles.14 Evaluation of toxicity over 24 hours or 48 hours 
by alamarBlue™ redox assay showed that at 0.1 mM con-
centration, nanoformulations of IDV (Figure 1A) and RTV 
with P188 and mPEG-DSPE as surfactants (Figure 1B), and 
EFV (Figure 1C) induced little or no HBMEC toxicities. 
The viability of endothelial cells exposed to these nanofor-
mulations was similar to that of cells exposed to free ART. 
These values were not significantly different from those of 
cells not exposed to drug (Figure 1A–C). Higher concentra-
tions of H2009 (0.27 mM) significantly increased toxicity 
in HBMEC (Figure 1D). Nanoformulations of RTV and 
ATV with P407 as surfactant (H2019 and H3019) or coated 
with folate-P407 (H2020 and H3020) induced more toxicity 
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in HBMEC compared with untreated cells (Figure 1E, 
#P , 0.0001; **P , 0.01, *P , 0.05). Fluconazole was used 
to make surfactant-coated control nanoparticles, with homog-
enized (H5013 and H5014) and milled (M5004 and M5006) 
formulations. At 0.1 mM concentration, these surfactant 
controls did not induce cytotoxicity (Figure 1F).
MP-endothelial cell nanoART transfers
Our previous works showed that nanoART could be loaded 
into human MDM and gradually released over time.14,17,22 
To determine whether nanoART released by MP can be 
transferred to cells of the brain  endothelium, we exposed 
HBMEC to conditioned media from MDM loaded with nano-
ART. Immunofluorescence analyses showed that following 
2 hours of exposure of HBMEC to MDM-conditioned 
media, uptake of nanoART by endothelial cells was seen for 
all formulations tested (Figure 2B and C). The endothelial 
nature of our primary HBMEC was confirmed by stain-
ing with the  endothelium-specific marker von Willebrand 
factor  (Figure 2A), data showed DiO-labeled HBMEC 
(Figure 2D) and accumulation of nanoformulated drugs 
around the endothelial cell body and nucleus (Figure 2C 
and F and  Figure 3). To determine whether nanoART can be 
transferred from MP to the brain endothelium during direct 
cell-to-cell contact, we cocultured HBMEC with human 
monocytes containing nanoART. Following 2 hours of 
coculture, transfer of nanoART from monocytes to HBMEC 
was observed for all ART nanoformulations and nanoART 
accumulated around the endothelial cell body and nucleus 
(Figure 2E and F and Figure 3).
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Figure 1 Effect of nanoformulated crystalline antiretroviral drugs on human brain microvascular endothelial cell (HBMEC) viability. Endothelial cells were loaded for 2 hours 
with four nanoformulations of indinavir (IDV) (A), six nanoformulations of ritonavir (RTV) (B and E), two nanoformulations of atazanavir (ATV) (D), or efavirenz (EFV) (C) 
at 0.1 mM. H2009 was used at 0.18 mM and 0.27 mM. Controls consisted of untreated cells and cells exposed to similar concentrations of free (without nanoparticles [NP]) 
IDV, RTV, or EFV (IDV-no NP, RTV-no NP, EFV-no NP). Additional controls consisted of cells treated with similar concentrations of surfactant or combination of surfactants, 
and cells exposed to fluconazole alone (without surfactants, F-no NP) (F). Following drug loading, toxicity was assessed over 24 hours or 48 hours by alamarBlue™ assay. The 
ATV (H3019, H3020) and RTV (H2019, H2020) nanoformulations decreased HBMEC viability, but all other nanoformulated crystalline antiretroviral drugs at concentrations 
of 0.1 mM had minimal or no effect on HBMEC viability. Similar concentrations of free IDV, RTV, or EFV did not alter HBMEC viability. At 0.27 mM drug concentration, 
increased toxicity was observed in cells exposed to H2009. All surfactants and fluconazole controls had no major effect on HBMEC viability.
Notes: For each experimental condition, n = 3. Figure shown is representative of three independent experiments. *P , 0.05; **P , 0.01; ***P , 0.001; #P , 0.0001.
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To further verify whether nanoART transferred to 
HBMEC enter endothelial cells, confocal microscopy was 
 performed. This was done with the understanding that 
such events could increase the likelihood of nanoART 
passing though the BBB. When HBMEC are exposed to 
monocytes containing nanoART (H2013 [Figure 3A, B, 
and D] and H3020 [Figure 3E]) or exposed to MDM-
conditioned medium (H2013 [Figure 3C]), nanoART 
entered endothelial cells. Analyses using the XZ or 
YZ line scan mode of the Olympus confocal imaging 
program demonstrated localization of nanoART in the 
cells cytoplasm, membrane-bound vesicles, and nucleus, 
with nanoART colocalized with endothelial cells vesicles 
(Figure 3, orange arrows). Confocal imaging also showed 
green membrane-bound vesicles in HBMEC (Figure 3, 
green, white arrows) and some nanoART inside HBMEC 
not colocalized with membrane-bound vesicles (Figure 3, 
red, white arrows).
B E
C F
A D
Figure 2 Uptake of nanoformulated crystalline antiretroviral drugs (nanoART) by human brain microvascular endothelial cells (HBMEC) following endothelial-mononuclear 
phagocyte cocultivation. (A–C) Primary HBMEC were exposed for 2 hours to conditioned media from monocyte-derived macrophages (MDM) loaded with rhodamine-
labeled efavirenz (P4004) as described in the Methods section; HBMEC were then washed three times with phosphate buffered saline to remove MDM-conditioned 
media, and analyzed by fluorescence microscopy. Panels (B and C) show endothelial cells uptake of nanoART (orange-yellow color) released by MDM. Staining with the 
endothelium-specific marker, von Willebrand factor (green, A) confirmed the endothelial nature of our primary HBMEC. (D–F) Primary HBMEC labeled with DiO (green, D) 
were cocultured for 2 hours with monocytes loaded with rhodamine-labeled ritonavir (H2013), washed to remove monocytes, and analyzed by fluorescence microscopy. 
Panels (E and F) show endothelial cells uptake of nanoART (orange-yellow color) during endothelial-monocyte cocultivation.
Note: All panels are at 200× magnification.
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FACS quantification of nanoART in MP
To further analyze nanoART uptake and transfer through 
MP-endothelial cell communication, we quantified the levels 
of nanoART in MP before and after coculture. Data showed 
strong uptake of nanoART by MP, with 56% and 94.9% of 
MDM positive for rhodamine when cells were exposed to 
0.1 mM and 0.5 mM IDV nanoformulations, respectively 
(Figure 4A and B). Similarly, 97.6% and 98.6% of monocytes 
stained positive for rhodamine when cells were exposed to 
0.1 mM and 0.5 mM RTV nanoformulations, respectively 
(Figure 4C and D). Transfer of nanoART from MDM to brain 
endothelial cells following coculture was associated with a 
decrease of nanoART levels in monocytes (Figure 4A–E). 
In fact, when monocytes were loaded with 0.1 mM IDV or 
RTV nanoformulations, 2 hours of coculture with HBMEC 
decreased nanoART levels in monocytes by 83% (IDV) 
and 71% (RTV) (Figure 4E, P , 0.001). For monocytes 
loaded with 0.5 mM IDV or RTV nanoformulations, 2 hours 
A C
B D
E
20.0 µM
Cell surfaceCell surface
Cell surface
Insert
Insert
YZ image
(side view)
YZ image
(side view)
YZ image
(side view)
XZ image
(side view)
XZ image
(side view)
XZ image
(side view)
XZ image
(side view)
YZ image
(side view)
Cell surface
Figure 3 Endothelial cell nanoformulated crystalline antiretroviral drug (nanoART) uptake follows mononuclear phagocyte cocultivation. (A and B) Uptake of rhodamine-
labeled ritonavir, H2013 (orange-yellow color) by primary human brain microvascular endothelial cells (HBMEC) (stained with DiO [green] and DAPI [blue for nucleus]) 
during endothelial-monocyte communication is visualized by confocal microscopy. Smaller nucleus (white arrow heads) shows monocytes (not removed during washes) in 
close cell-cell communication with HBMEC. (C and D) HBMEC (stained with DiO [green] and DAPI [blue for nucleus]) uptake of DiD-labeled ritonavir, H2013 (orange-
yellow color) from monocyte-derived macrophage-conditioned media (C), and during direct endothelial-monocyte communication (D). (E) HBMEC uptake of DiD-labeled 
folated-modified atazanavir (H3020) (orange-red color) during direct endothelial-monocyte communication.
Notes: Each set of images consists of a top view of cells and nanoART particles, a side view of the XZ optical line scan through the yellow line, and a side view of the YZ 
optical line scan through the purple line. From those side view optical images, nanoART particles are seen inside the cells (arrows). For all panels, orange-colored arrows 
indicate nanoART (red fluorescence) colocalized with HBMEC vesicles; white arrows indicate nanoART (red fluorescence) or DiO-labeled membrane-bound vesicles (green 
fluorescence) that are not colocalized. Magnifications are at 630× (A), 720× (E), and 1000× (B–D).
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of coculture with HBMEC decreased nanoART levels in 
monocytes by 44.5% (IDV) and 49.6% (RTV) (Figure 4E, 
P , 0.001).
FACS quantification of nanoART  
in HBMEC following MP coculture
FACS analysis of HBMEC (DiD-labeled) cocultured 
with monocytes loaded with rhodamine-labeled RTV 
nanoformulations showed that within the 2 hours of coculture, 
nanoART were transferred to over 46% of HBMEC (Figure 5A 
and B). To determine the effect of folate modification on the 
transfer of nanoART from monocytes to HBMEC, we quanti-
fied the levels of folate-coated nanoART (H2020 and H3020) 
and their corresponding nonfolate formulations (H2019 
and H3019) in HBMEC following coculture of endothelial 
cells with monocytes carrying nanoART. FACS analysis of 
HBMEC after 2 hours of coculture with monocytes loaded 
with DiD-labeled nanoART showed transfer of ATV (H3019) 
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Figure 4 Transfer of nanoformulated crystalline antiretroviral drugs (nanoART) from mononuclear phagocyte to human brain microvascular endothelial cells (HBMEC) 
follows cell cocultivation. Monocytes loaded with 0.1 mM or 0.5 mM rhodamine-labeled indinavir (IDV) (H1013b, A and B) or ritonavir (RTV) (H2013, C and D) 
nanoformulations were cocultured for 2 hours with HBMEC as described in the Methods section, and the levels of nanoART in monocytes before and after coculture 
quantified by fluorescence-activated cell sorting analysis. Coculture of monocytes loaded with 0.1 mM IDV (A) or RTV (C) nanoART with HBMEC decreased IDV and RTV 
nanoART levels in monocytes by 83% (A, dotted line, and E), and 71% (C, dotted line, and E). Coculture of monocytes loaded with 0.5 mM IDV (B) or RTV (D) nanoART 
with HBMEC decreased IDV and RTV nanoART levels in monocytes by 44.5% (B, dotted line, and E), and 49.6% (D, dotted line, and E).
Notes: ***P , 0.001. Each experimental condition was performed in triplicate, and data shown are representative of four independent experiments.
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and folate-coated ATV (H3020) nanoformulations to 52% 
and 64% of HBMEC, respectively (Figure 5C). Similarly, 
coculture of HBMEC with monocytes loaded with DiD-
labeled RTV formulations showed transfer of RTV (H2019) 
and folate-coated RTV (H2020) nanoformulations to 50% 
and 77.3% of HBMEC, respectively (Figure 5D).
Antiretroviral activity and brain 
penetration of folate-coated nanoART
To determine the antiretroviral activity of nanoART, the 
expression of HIV-1 gag in infected folate-coated nanoART-
treated and -untreated (control) animals was quantitated 
in spleen and brain tissues by qRT-PCR. In folate-coated 
 nanoART-treated mice, the level of HIV-1 gag gene expres-
sion was at the limit of sensitivity for the assay, while signifi-
cantly higher levels of HIV-1 gag expression were observed in 
untreated mice (Figure 6A, P , 0.01). To determine whether 
the differences in viral gene expression could be explained 
by differences in the numbers of human lymphocytes in 
the brain, expression of the human T-cell-specific marker 
CD45 gene expression was determined. CD45 expression 
levels were similar in brain tissues of untreated and treated 
mice (Figure 6B), indicating equal infiltration of human 
T lymphocytes into the CNS. Microglia activation and 
macrophage infiltration into the brain were determined by 
quantitating RNA expression of the cell adhesion molecule 
CD11b. CD11b gene expression was two-fold lower in brain 
tissues from folate-coated nanoART-treated mice compared 
with untreated mice (P , 0.01, Figure 6C).
Tissue and sera drug levels in PBL-reconstituted HIV-1-
infected mice treated with two doses of 250 mg/kg folate-
coated  nanoART, H2020 and H3020 (Day 0 and Day 7), are 
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Figure 5 Quantification of nanoformulated crystalline antiretroviral drug (nanoART) transfer from mononuclear phagocytes to human brain microvascular endothelial cells 
(HBMEC). (A and B) HBMEC fluorescently labeled with DiD (excitation 644 nm) were cocultured for 2 hours with monocytes loaded with rhodamine-labeled ritonavir 
(RTV) nanoformulations (excitation 543 nm). Monocytes were removed by three to five washes and HBMEC harvested and analyzed by fluorescence-activated cell sorting. 
Endothelial-monocyte communication resulted in nanoART transfer to over 46% of HBMEC. (C and D) Unlabeled HBMEC were cocultured for 2 hours with monocytes loaded 
with DiD-labeled atazanavir (ATV) (C) and RTV (D) nanoformulations. Monocytes were removed by three to five washes and HBMEC harvested and analyzed by fluorescence-
activated cell sorting. Endothelial-monocyte communication resulted in transfer of ATV (H3019) and folate-coated ATV (H3020) nanoformulations to 52% and 64.4% of 
HBMEC, respectively (C), and also resulted in transfer of RTV (H2019) and folate-coated RTV (H2020) nanoformulations to 50% and 77.3% of HBMEC, respectively (D).
Note: Each experimental condition was performed in triplicate, and data shown are representative of two independent experiments.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2382
Kanmogne et al
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
9.
93
.1
0.
13
2 
on
 0
3-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2012:7
shown in Figures 6D and E. The highest ATV levels were 
observed in the liver and spleen (4372 ng/g and 2441 ng/g 
tissue, respectively). RTV levels were somewhat less than 
ATV levels in the spleen but similar to ATV levels in all other 
tissues. Next, we compared drug levels in the serum and 
brain of mice treated with folate-coated nanoART (H2020 
and H3020) and the corresponding noncoated nanoART 
(H2019 and H3019) (Figure 6E). Interestingly, brain ATV 
and RTV levels in folate-coated nanoART-treated mice were 
three- to four-fold higher than in mice treated with noncoated 
nanoART. Brain ATV and RTV levels in animals treated 
with folate-coated nanoART were 33 ng/g and 34.5 ng/g, 
respectively, while ATV and RTV levels in animals treated 
with  nonmodified nanoART were 10.6 ng/g and 4.1 ng/g, 
respectively (Figure 6E, P , 0.02). In contrast, serum ATV 
concentrations were similar in mice treated with folate-
coated nanoART (202.2 ng/mL) and nonmodified nanoART 
(244.1 ng/mL). Serum RTV concentrations were also similar 
in mice treated with folate-coated nanoART (145.4 ng/mL) 
and noncoated nanoART (146.5 ng/mL).
Discussion
A major limitation of cART rests in their inability to pen-
etrate the CNS. Thus, even when systemic viral load is con-
trolled with ART, the brain remains an HIV sanctuary.6–9 We 
hypothesize that nanomedicine-based ART could effect viral 
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Figure 6 Antiretroviral activity and drug biodistribution of folate-coated nanoformulated crystalline antiretroviral drugs (nanoART). Folate-coated nanoART were injected 
subcutaneously on Days 0 and 7 as a combination of atazanavir (ATV) (H3020) and ritonavir (RTV) (H2020) (250 mg/kg each) to peripheral blood lymphocyte-NOD/scid-γcnull 
mice infected with HIV-1ADA 12 hours before initial nanoART dose. Peripheral blood and tissues were collected on Day 14 after initial nanoART injection, followed by RNA 
extraction and real-time polymerase chain reaction for HIV-1 gag (A), human CD45 (B), and mice CD11b (C), and normalized to glyceraldehyde-3-phosphate dehydrogenase 
mRNA. NanoART-treated mice showed a significant decrease in HIV-1 gag in the spleen and brain (A, *P , 0.01), and CD11b RNA in brain (C, *P , 0.04). CD45 levels were 
similar in the brains of treated and untreated mice (B). For (A–C), values are expressed as mean ± standard error of the mean (bar ± whisker). (D) Tissue (ng/g) and serum 
(ng/mL) drug levels in mice at 14 days after initial nanoART injection. (E) Serum (ng/mL) and brain (ng/g) drug levels in HIV-1-infected peripheral blood lymphocyte-NOD/
scid-γcnull mice treated with uncoated nanoART (H3019 and H2019) or folate-coated nanoART (H3020 and H2020) (250 mg/kg ATV/RTV, subcutaneously).
Notes: Significantly higher levels of ATV and RTV were detected in brain tissues of infected animals treated with folate-coated nanoART, compared with animals treated 
with uncoated nanoformulations (*P , 0.02). Drug levels are expressed as median ± 25th and 75th percentiles due to non-normality of data. For panels (A–C), n = 8 for 
control, and n = 10 for the drug-treated group. For panels (D and E), n = 8 in each group.
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eliminations from sanctuaries such as the CNS. Our prior 
works demonstrated efficient cellular uptake, distribution, 
and release of nanoART by MP in both in vitro and animal 
models of human disease15–17,20–22 and showed limited toxicities 
in cells and tissue.14 Thus, we also hypothesize that circulating 
monocyte-macrophages carrying nanoART could transfer the 
drug to HBMEC, the major cells of the BBB, through cell-
cell communication and, as such, may enhance ART entry 
into the brain. In the current report, we investigated HBMEC 
uptake, in vivo drug distribution, antiretroviral activity, and 
CNS penetration of nanoART. To first ensure that nanoART 
would not cause adverse effects to brain endothelial cells, 13 
protease inhibitor and non-nucleoside reverse transcriptase 
inhibitor formulations were prepared by homogenization, wet 
milling, or sonication and assessed for cytotoxicities. Nine 
nanoformulations showed little or no HBMEC cytotoxicity 
at 0.1 mM, a concentration that significantly suppresses viral 
replication for more than 2 weeks following a single nanoART 
exposure.17,22 The increased endothelial toxicity observed with 
four of the nanoformulations could be due to the surfactant, 
as these were the only formulations prepared using P407.
We also demonstrated efficient uptake of nanoART by brain 
endothelial cells. During such endothelial cell-monocytes/
MDM engagements, increased uptake of nanoART by 
HBMEC correlated with decreased levels of nanoART in 
donor monocytes and macrophages. These results suggested 
a novel means of ART CNS delivery. Efficient uptake and 
release of nanoART by MP was shown in our works.17,20,22 
Our current data showing efficient uptake of nanoART by 
HBMEC exposed to MDM-conditioned media and during 
direct endothelial-MP contact support the idea that  nanoART 
released by MDM can be taken up by cells of the BBB, and 
that nanoART can be transferred from the periphery to the 
brain. Confocal microscopy analyses showed nanoART 
particles inside endothelial cells, including cell vesicles 
and nucleus. Interestingly, folate modification enhanced the 
transfer of nanoART from MP to HBMEC, and was associ-
ated with enhanced BBB penetration in vivo. Thus, nanoART 
formulated by modifying nanoparticle surfaces with targeted 
molecules could increase drug uptake into HBMEC and 
accelerate CNS drug entry. The mechanisms of this enhanced 
uptake and CNS entry of folate-coated nanoART remains 
to be determined, including whether the process involves 
carrier-mediated transport, receptor-mediated endocytosis, 
or adsorptive endocytosis of the drug-laden particles. It has 
been shown that folic acid can be transported across the cell 
membrane by using the reduced folate carrier, the folate 
receptor (FR), or the folic acid pump.29,30 Although there are 
limited numbers of FR on the BBB, FR expression can facili-
tate drug entry into the CNS.30,31 It has also been reported that 
mice and human choroid plexus express substantial levels of 
FR, and these FR are potential therapeutic targets for choroid 
plexus tumors.32 Other tumors overexpress the FR, and folate 
modification has been shown to significantly improve cellular 
uptake and efficacy of anticancer drugs.33–36 Tagging folate to 
gene therapy vectors and immunotherapeutic agents has also 
been shown to improve drug delivery.34,37,38
It is well known that other receptors, such as the transferrin 
and mannose receptors, expressed on brain endothelial 
cells can also facilitate the transport of nanoparticles across 
the BBB.39 A five-fold increase in didanosine uptake was 
demonstrated when the drug was conjugated to mannan-
coated nanoparticles, with significantly increased didanosine 
concentration in the spleen, brain, and lymph nodes.40 
The authors suggested that mannan-coated nanoparticles 
targeted didanosine to cells by mannosyl receptor-mediated 
endocytosis.40 In vitro studies also showed increased endothelial 
uptake of solid lipid ATV and transferrin-tagged saquinavir 
nanoparticles compared with nontagged drugs.41,42 The current 
study shows localization of nanoART in endothelial cell 
vesicles, suggesting that vesicular transport may be involved 
in nanoART uptake and trafficking in HBMEC. Future 
investigations will explore the types of vesicles involved and 
the molecular mechanisms through which endothelial cells 
uptake nanoART during endothelial-MP communication.
NanoART treatment of HIV-1-infected humanized mice 
was associated with significantly decreased viral loads. Mice 
were reconstituted with human peripheral blood  lymphocytes; 
the leukocyte common antigen CD45 is abundantly expressed 
in human lymphocytes, and HIV infection is often associ-
ated with increased infiltration of leukocytes into the CNS, 
including T lymphocytes.43,44 Our study showed equal infiltra-
tion of human T lymphocytes into the CNS of untreated and 
nanoART-treated infected mice, indicating that the observed 
differences in viral gene expression are not due to differences 
in the numbers of human lymphocytes in the brain. NanoART 
treatment of infected mice was also associated with signifi-
cantly decreased brain CD11b RNA levels. This suggested that 
in addition to reducing viremia, nanoART decrease microglial 
activation and/or macrophage transmigration into the brain. 
Our previous works in vitro also showed that nanoART at 
0.1 mM can suppress HIV replication in macrophages for 
up to 15 days.17,22 Overall, the current study showed that 
this nanoART concentration induced limited cytotoxicity in 
primary HBMEC. Significantly, we show transfer of nanoART 
from MP to cells of the brain endothelium through direct 
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MP-endothelial cell communication, with increased drug 
transfer and brain penetration for folate-coated nanoART, 
correlating with decreased CNS viral load and decreased 
MP activation. Because most of the current ART drugs have 
a very poor BBB penetration, treatment of HIV CNS infection 
remains elusive and the brain remains a major viral reservoir. 
Thus, it is critical to devise strategies to improve the penetra-
tion of ART drugs into the CNS. Our current study suggests 
that nanoformulations of ART drugs could improve drug entry 
into the CNS and other viral sanctuaries, and thus help reduce 
viral-associated injury in these tissues and organs.
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Materials and methods
Preparation and characterization of nanoART
The surfactants used for nanoART included poloxamer-188 
and -407 (P188, P407 Sigma-Aldrich); N-(carbonyl-
methoxypolyethyleneglycol 2000)-1,2 sn-glycero-3-
phosphoethanolamine (mPEG
2000
-DSPE; Genzyme, 
Cambridge, MA); sodium dodecyl sulfate (SDS; Bio-Rad 
Laboratories, Hercules, CA); poly(lactic-coglycolic acid) 
(PLGA; Sigma-Aldrich); and cetyltrimethyl ammonium 
bromide (CTAB; Sigma-Aldrich) (Table 1). Using these 
surfactants, nanoART were manufactured from three 
protease inhibitors (IDV, RTV, ATV), and one non-nucleoside 
reverse transcriptase inhibitor (EFV) as we previously 
described.14,17,22 Briefly, surfactants were resuspended in 
10 mM HEPES, pH 7.8, and freebase drug was added (0.6% 
by weight). Combinations of drug and surfactant were as 
follows: ATV in 0.5% P188 or P407; IDV in 0.5% P188 and 
0.5% SDS, 0.1% mPEG
2000
DSPE; and RTV in 0.3% P188 
and 0.1% mPEG
2000
DSPE. A homogeneous dispersion was 
formed by agitation with an Ultraturrax T-18 rotor-stator 
mixer (IKA® Works Inc, Wilmington, NC). For preparation 
of suspensions by homogenization, mixtures were transferred 
to an Avestin C5 high-pressure homogenizer (Avestin, Inc, 
Ottawa, ON, Canada) and extruded at 20,000 pounds per 
square inch for about 30 passes or until the desired particle 
size was reached.14,17 Particle size, polydispersity, and surface 
charge (zeta potential) were determined by dynamic light 
scattering using a Malvern Zetasizer Nano Series Nano-ZS 
(Malvern Instruments Inc, Westborough, MA). After the 
desired particle size was achieved, samples were centrifuged 
at 10,000 × g for 30 minutes at 4°C. The resulting pellet 
was resuspended in surfactant solution containing 9.25% 
sucrose to adjust tonicity. For preparation of nanosuspensions 
by wet milling, mixtures were transferred to a NETZSCH 
MicroSeries Wet Mill (NETZSCH Premier Technologies, 
LLC, Exton, PA) with 50 mL of 0.8 mm grinding media 
(zirconium ceramic beads, Saint-Gobain ZirPro, La Pontet, 
France). The sample was milled for 30 minutes to 1 hour at 
speeds ranging from 600 rpm to 4320 rpm until the desired 
particle size was achieved.45,46 Nanoparticles of fluconazole 
(IVAX Pharmaceuticals, Miami, FL) were manufactured 
using the same methods mentioned previously.14 Drug 
concentrations in the final suspensions were determined using 
HPLC as previously described.17
EFV nanoparticles were made by sonication; 6 g of 
PLGA, RESOMER RG 752 H (Sigma-Aldrich) was added 
to 50 mL dichloromethane (HPLC grade) with 1% cetylt-
rimethyl ammonium bromide (CTAB; Sigma-Aldrich) and 
mixed until complete dissolution. Freebase EFV (1.25 g) 
was added to the dichloromethane/PLGA solution and mixed 
to obtain complete dissolution. This solution was added to 
a 1% polyvinyl alcohol (PVA) (Sigma-Aldrich) solution 
precooled in an ice bath. The drug/surfactant solution was 
placed in an ice bath and the sample sonicated using a Cole 
Parmer Ultrasonic Processor (Vernon Hills, IL) at 50% 
amplitude for 10 minutes. Particle size was determined by 
dynamic light scattering using a Zetasizer. The sonication 
time was increased at 2-minute intervals up to a maximum of 
16 minutes total if the particle size was greater than 1.5 µM. 
The samples were characterized by light microscopy (20× 
magnification). The remaining suspension was vortexed and 
mixed at an adequate speed overnight at room temperature, 
then collected after 24 hours and centrifuged at a speed of 
8100 × g for 20 minutes at 5°C. After decanting the superna-
tant, the pellet was resuspended in 75 mL of filtered, reverse 
osmosis (RO) water and the samples centrifuged again at 
a speed of 8100 × g for 20 minutes at 5°C. The pellet was 
resuspended in 1% mannitol in RO water (Sigma-Aldrich) 
solution for lyophilization. The particle size was again 
measured using a Zetasizer. Drug concentration in the final 
nanoART suspension was determined using HPLC as previ-
ously described.17
NanoART formulations were imaged by scanning 
electron microscopy as previously described.14,17,22 Briefly, 
10 µL of nanosuspension was diluted in 1.5 mL of 0.2 µM 
filtered double-distilled water. The diluted suspension was 
mixed, and a 50 µL aliquot was transferred to a filtration 
apparatus (Swinnex 13 polypropylene f ilter holder, 
Millipore, Billerica, MA) assembled with a 0.2 µM prewetted 
polycarbonate filter membrane (Nuclepore Track-Etched, 
Whatman International Ltd, Kent, ME). The entire solution 
volume was pulled through the filtration membrane by 
vacuum. The membrane was washed with 500 µL of filtered 
double-distilled water. The membrane was allowed to dry for 
24 hours, fixed to an aluminum pin stub using double-stick 
conductive carbon tape, and sputter coated with palladium 
(EMITECH K575X, Quorum Technologies, Ashford, Kent, 
UK). The samples were affixed to the specimen stub and 
imaged using a Hitachi S4700 Field Emission Scanning 
Electron Microscope (Hitachi High Technologies America, 
Inc, Schaumburg, IL).
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